118 related articles for article (PubMed ID: 23474554)
1. Second-line therapy in pancreatic cancer.
Skoura E; Syrigos KN; Saif MW
JOP; 2013 Mar; 14(2):133-4. PubMed ID: 23474554
[TBL] [Abstract][Full Text] [Related]
2. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy of pancreatic cancer.
Chaulagain CP; Ng J; Goodman MD; Saif MW
JOP; 2013 Mar; 14(2):119-22. PubMed ID: 23474550
[TBL] [Abstract][Full Text] [Related]
5. Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
Ur Rehman SS; Lim K; Wang-Gillam A
Expert Rev Anticancer Ther; 2016 May; 16(5):485-92. PubMed ID: 27043737
[TBL] [Abstract][Full Text] [Related]
6. [Non-surgical treatment for pancreatic cancer].
Okusaka T; Ueno H; Ikeda M; Morizane C
Nihon Shokakibyo Gakkai Zasshi; 2006 Apr; 103(4):391-7. PubMed ID: 16629457
[No Abstract] [Full Text] [Related]
7. First-line treatment for advanced pancreatic cancer.
Kothari N; Saif MW; Kim R
JOP; 2013 Mar; 14(2):129-32. PubMed ID: 23474553
[TBL] [Abstract][Full Text] [Related]
8. [S-1 for gastric cancer-S-1 monotherapy and its progress].
Shitara K; Sakata Y; Kudou T; Munakata M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():43-51. PubMed ID: 16897971
[TBL] [Abstract][Full Text] [Related]
9. Advancements in the management of pancreatic cancer: 2013.
Saif MW
JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
[TBL] [Abstract][Full Text] [Related]
10. Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer.
Alsamarai S; Zergebel C; Zhang J; Furuie T; Urrea PD; Saif MW
JOP; 2008 Mar; 9(2):185-91. PubMed ID: 18326927
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0302.
Komatsu Y; Yuuki S; Fuse N; Takei M; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Ohizumi H; Watanabe M; Akita H; Sakata Y; Asaka M
Jpn J Clin Oncol; 2005 Feb; 35(2):88-9. PubMed ID: 15709093
[TBL] [Abstract][Full Text] [Related]
12. [CPT-11 combined chemotherapy for metastatic gastric cancer].
Narahara H; Sugimoto N; Iishi H; Tatsuta M
Gan To Kagaku Ryoho; 2004 Nov; 31(12):1973-7. PubMed ID: 15570923
[TBL] [Abstract][Full Text] [Related]
13. [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Goto A
Gan To Kagaku Ryoho; 2006 Jul; 33(7):896-900. PubMed ID: 16835475
[TBL] [Abstract][Full Text] [Related]
14. [Controversy of treatment for advanced colorectal cancer--intermedisine].
Sato A; Shimada K; Taguchi S
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1260-9. PubMed ID: 14518404
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer.
Choi HJ; Kim NK; Keum KC; Cheon SH; Shin SJ; Baik SH; Choen JH; Rha SY; Roh JK; Jeung HC; Chung HC; Ahn JB
Radiother Oncol; 2008 Jun; 87(3):361-6. PubMed ID: 18439695
[TBL] [Abstract][Full Text] [Related]
16. [A case of recurrent pancreatic cancer effectively responding to S-1 combined irinotecan third-line chemotherapy with PSK].
Saji O; Ishii M; Kobayashi H; Sumiyoshi K; Asano T; Iwata K; Okamura R; Kobayashi S; Koizumi S; Otsubo T
Gan To Kagaku Ryoho; 2013 Oct; 40(10):1409-12. PubMed ID: 24196082
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
Levy A; Chargari C; Huguet F; Védrine L; Deutsch E
Pancreas; 2012 Aug; 41(6):973-4. PubMed ID: 22781912
[No Abstract] [Full Text] [Related]
18. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer.
Shitara K; Komatsu Y; Yuki S; Munakata M; Muto O; Shimaya S; Sakata Y
Oncology; 2008; 75(1-2):67-70. PubMed ID: 18753799
[TBL] [Abstract][Full Text] [Related]
20. [Long-term repeatable chemotherapy for patients with advanced pancreatic cancer].
Yamamitsu S; Kimura H; Yamada Y; Inui N; Hiyama S; Hirata K; Kimura Y; Shirasada T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():213-8. PubMed ID: 16898005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
